06 Mar 2018

Stephenson Harwood advises Acacia Pharma on €190 million Euronext Brussels IPO

Linkedin

Law firm Stephenson Harwood LLP has advised Acacia Pharma Group on its €190 million IPO on Euronext Brussels.

British-based Acacia Pharma specialises in the research and development of supportive care medicines. The group, which also has US operations in Indianapolis, will use the funds for a targeted push at a specialised market in North America, with its first product, treating post-operative nausea and vomiting, expected to be launched in 2019.

The Initial Global Offer was priced at €3.60 per share, raising gross proceeds of €40 million. Based on the offer price, the total market capitalisation of Acacia Pharma at the commencement of conditional dealings on Monday 5 March was approximately €190 million. Acacia Pharma's listing is the largest on Euronext since 2015 and is the first IPO of a British-based biotech company in 2018.

The Stephenson Harwood team was led by London-based corporate partner Anthony Clare and included senior associate David Dowding, associates Tom Parker and Maddie Alexander-Finch and trainee Christina Olliver, with support from John Meehan (tax) and Barbara Allen and Anika Chandra (incentives).

Linkedin

KEY CONTACT

Anthony Clare

Anthony Clare
Partner

T:  +44 20 7809 2326 M:  +44 7711 345 399 Email Anthony | Vcard Office:  London

David Dowding

David Dowding
Senior associate

T:  +44 20 7809 2162 M:  +44 77 1242 9038 Email David | Vcard Office:  London

Thomas Parker

Thomas Parker
Associate

T:  +44 20 7809 2596 M:  +44 78 8131 3344 Email Thomas | Vcard Office:  London

MEDIA CONTACT

Andrew Rieley
Head of communications

T: +44 20 7809 2886 
Email Andrew